Preempting and preventing drug-induced liver injury

被引：19

作者：

Aithal, Guruprasad P. ^{[1
]}

Daly, Ann K. ^{[2
]}

机构：

[1] Nottingham Univ Hosp Natl Hlth Serv Trust, Nottingham Digest Dis Ctr, Natl Inst Hlth Res Biomed Res Unit, Nottingham, England

[2] Newcastle Univ, Inst Cellular Med, Sch Med, Newcastle Upon Tyne, Tyne & Wear, England

来源：

NATURE GENETICS | 2010年 / 42卷 / 08期

关键词：

NONSTEROIDAL ANTIINFLAMMATORY DRUGS; THERAPEUTIC ARTHRITIS RESEARCH; RANDOMIZED CONTROLLED-TRIAL; HEPATOTOXICITY; EVENT; PATHOGENESIS; LUMIRACOXIB; IBUPROFEN; NAPROXEN; TARGET;

D O I：

10.1038/ng0810-650

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

A new study reports that susceptibility to drug-induced liver injury by the cyclooxygenase 2 (COX-2) inhibitor lumiracoxib is associated with a human lymphocyte antigen (HLA) class II haplotype. This finding suggests that those at risk of hepatotoxicity can be identified by HLA genotyping, raising the possibility that lumiracoxib can be resurrected as a useful drug.

引用

页码：650 / 651

页数：3

共 15 条

[1] Aithal Guruprasad P, 2007, Clin Liver Dis, V11, P563, DOI 10.1016/j.cld.2007.06.004
[2] HLA-B☆5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
Daly, Ann K.
Donaldson, Peter T.
Bhatnagar, Pallav
Shen, Yufeng
Pe'er, Itsik
Floratos, Aris
Daly, Mark J.
Goldstein, David B.
John, Sally
Nelson, Matthew R.
Graham, Julia
Park, B. Kevin
Dillon, John F.
Bernal, William
Cordell, Heather J.
Pirmohamed, Munir
Aithal, Guruprasad P.
Day, Christopher P.
[J]. NATURE GENETICS, 2009, 41 (07) : 816 - U71
[3] Acute and clinically relevant drug-induced liver injury:: a population based case-control study
de Abajo, FJ
Montero, D
Madurga, M
Rodríguez, LAG
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (01) : 71 - 80
[4] Genetics of liver disease: Immunogenetics and disease pathogenesis
Donaldson, PT
[J]. GUT, 2004, 53 (04) : 599 - 608
[5] DONALDSON PT, 2010, J HEPATOL IN PRESS
[6] Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
Farkouh, ME
Kirshner, H
Harrington, RA
Ruland, S
Verheugt, FW
Schnitzer, T
Burmester, GR
Mysler, E
Hochberg, MC
Doherty, M
Ehrsam, E
Gitton, X
Krammer, G
Mellein, B
Gimona, A
Matchaba, P
Hawkey, CJ
Chesebro, JH
[J]. LANCET, 2004, 364 (9435) : 675 - 684
[7] A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience
Goldkind, L
Laine, L
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 (04) : 213 - 220
[8] HLA association of amoxicillin-clavulanate-induced hepatitis
Hautekeete, ML
Horsmans, Y
van Waeyenberge, C
Demanet, C
Henrion, J
Verbist, L
Brenard, R
Sempoux, C
Michielsen, PP
Yap, PSH
Rahier, J
Geubel, AP
[J]. GASTROENTEROLOGY, 1999, 117 (05) : 1181 - 1186
[9] Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study
Hirata, K.
Takagi, H.
Yamamoto, M.
Matsumoto, T.
Nishiya, T.
Mori, K.
Shimizu, S.
Masumoto, H.
Okutani, Y.
[J]. PHARMACOGENOMICS JOURNAL, 2008, 8 (01) : 29 - 33
[10] Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis
Kindmark, A.
Jawaid, A.
Harbron, C. G.
Barratt, B. J.
Bengtsson, O. F.
Andersson, T. B.
Carlsson, S.
Cederbrant, K. E.
Gibson, N. J.
Armstrong, M.
Lagerstrom-Fermer, M. E.
Dellsen, A.
Brown, E. M.
Thornton, M.
Dukes, C.
Jenkins, S. C.
Firth, M. A.
Harrod, G. O.
Pinel, T. H.
Billing-Clason, S. M. E.
Cardon, L. R.
March, R. E.
[J]. PHARMACOGENOMICS JOURNAL, 2008, 8 (03) : 186 - 195

← 1 2 →